Actively Recruiting
Phase 2 Study to Test the Safety and Effectiveness of IBI3002 Compared to Dupilumab and Placebo in Adults With Moderate to Severe Atopic Dermatitis
Led by Innovent Biologics (Suzhou) Co. Ltd. · Updated on 2026-02-13
120
Participants Needed
1
Research Sites
9 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of IBI3002 in adults with moderate to severe Atopic Dermatitis AD. This Phase 2, multicenter, randomized, double-blind, placebo-controlled study includes about 120 participants who meet specific diagnostic criteria and disease severity measures. The study aims to assess how IBI3002 compares to placebo and dupilumab in improving skin condition and symptom measures related to AD. Participants will be randomly assigned to one of six groups receiving different doses of IBI3002, dupilumab, or matched placebo. All treatments are given by subcutaneous injection at specified intervals. The study includes multiple dose levels of IBI3002 and a loading dose of dupilumab followed by regular dosing. Treatment effects will be assessed over a 16-week period, with additional evaluations up to 20 weeks. During the study, participants will undergo blood collection, clinical assessments including the Eczema Area and Severity Index EASI, Investigators Global Assessment for AD, and symptom rating scales. Safety and tolerability will be monitored through reports of adverse events and pharmacokinetic testing. The primary outcome is the percentage change in EASI score at Week 16, with other measures including immunogenicity and pharmacodynamic effects. Participation involves regular visits and assessments through the treatment and follow-up periods.
CONDITIONS
Brief Title
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
Research Team
M
Man Yang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here